→ The candid chief of Regeneron Pharmaceuticals $REGN Leonard Schleifer made a provocative suggestion to remedy the burgeoning US infrastructure crisis, citing research that emphasizes the issue is not just financial, but indeed a public health and safety hazard. For the next three years, he asserted in an NYT op-ed on Tuesday, “every American public company [should] be required to issue 1 percent of its equity in the form of new stock to a newly formed infrastructure ‘bank.’ Given that American public companies have a collective market capitalization of about $30 trillion, this would raise about $1 trillion in three years.”
He predicted his suggestion may not garner the enthusiasm of some companies or their shareholders. But this is hardly a burden, he argued, “given that 1 percent represents a typical daily fluctuation in many companies’ stock prices. And last year American public companies shelled out about $800 billion just to buy back their own stock.”
→ The Broad investigator Feng Zhang and the CRISPR experts who joined him in launching Sherlock Biosciences have closed out their launch round for the Cambridge, MA-based company. Zhang and his group raised $31 million from the A round, with Northpond Ventures, Baidu Ventures and Open Philanthropy Project in the syndicate. The raise gives Zhang $49 million in committed capital to work with. They’re using CRISPR and synthetic biology tech to develop molecular diagnostics.
→ Alder BioPharmaceuticals finally has a foot in the FDA door as the agency accepted their migraine drug for review. A latecomer to the CGRP party, eptinezumab is administered intravenously once every quarter — a standout quality according to little Alder, which faces daunting competition from Novartis/Amgen, Teva and Eli Lilly. If all goes well, the market will find out if they’re right early 2020.
→ London-based Autolus Therapeutics $AUTL has won an FDA orphan drug designation for its autologous T cell therapy targeting acute lymphoblastic leukemia. AUTO3 is genetically modified to express two chimeric antigen receptors — both CD19 and CD22 — and designed to address antigen escape, “a common cause of relapse” in pediatric ALL patients.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription